The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes passive agents (antibodies, targeted nano-devices, and ligands) and active agents (vaccines). An important goal is to take these new therapies into human clinical trials for testing.

Publications

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Whitten J, Tan T, Liu H, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C and Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

McDevitt MR, Ma, DS, Lai LT, Simon J, Frank RK, Borchardt P, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science. 2001 Nov 16;294(5546):1537-40.

Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova, Deen WM, Scheinberg DA, McDevitt MR. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12369-74. doi: 10.1073/pnas.0913667107. Epub 2010 Jun 21.

Maslak P, Dao T, Krug LD, Chanel S, Zhang R, Pinilla-Ibarz, Frattini M, Wolchok J, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16.

Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, Benezra R, Scheinberg DA. Selective killing of tumor neo-vasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010 Nov 15;70(22):9277-86. doi: 10.1158/0008-5472.CAN-10-2029. Epub 2010 Nov 2.

Office phone:
646-888-2190
Laboratory phone:
646-888-2205
David Scheinberg, Chairman, Molecular Pharmacology and Chemistry Program

At Work: Experimental Therapeutics Center Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.